Assignment of opsonic values to pneumococcal reference serum 007sp and a second pneumococcal OPA calibration serum panel (Ewha QC sera panel B) for 11 serotypes. Issue 51 (3rd December 2020)

• Record Type: Journal Article
• Authors: Burton, Robert L.; Kim, Han Wool; Lee, Soyoung; Kim, Hun; Seok, Jee-hyun; Ku, Kun Young; Seo, Jihye; Kim, Sun Jin; Xie, Jinfu; McGuinness, Debra; Skinner, Julie M.; Choi, Seuk Keun; Baik, Yeong Ok; Bae, Sejong; Nahm, Moon H.; Kim, Kyung-Hyo
• Is Part Of: Vaccine. Volume 38:Issue 51(2020)
• Page Start: 8145
• Page End: 8153
• Publication Date: 2020-12-03
• Subjects: 007sp -- Opsonophagocytic assay -- Pneumococcus -- Quality control sera -- Standardization -- Vaccines; Pn pneumococcal serotype -- PCV pneumococcal conjugate vaccine -- OPA opsonophagocytic killing assay -- MOPA multiplexed opsonophagocytic killing assay -- OI opsonic index -- BRC baby rabbit complement -- CI confidence interval -- CFU colony forming units -- GMOI geometric mean opsonic index -- CV coefficient of variation -- NA not applicable; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.10.085
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Pneumococcal conjugate vaccines (PCVs) have been effective in reducing the disease burden caused by Streptococcus pneumoniae . The first licensed PCV (PCV7) was composed of capsular polysaccharides from seven serotypes. This was followed by PCV10, then PCV13, and currently there are a number of higher valency vaccines in development. As part of licensure, new vaccine iterations require assessment of immunogenicity. Since some antibodies can be non-functional, measuring functional antibodies is desirable. To meet this need, opsonophagocytic assays (OPAs) have been developed. Previous studies have shown there can be significant variations in OPA results from different laboratories. We have previously shown that standardizing OPA data using reference serum 007sp can decrease this variation. To extend this approach to additional serotypes, a panel of sera was tested by five laboratories using a multiplexed OPA for serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20B, 22F, and 33F. Each sample was tested in five runs with 007sp tested three times in each run. Results were analyzed using a mixed effects ANOVA model. Standardization of the results significantly decreased the inter-laboratory variation for some serotypes. For serotypes 2, 8, and 11A, the variability was reduced by 40%, 45%, and 40%, respectively. For serotypes 12F, 17F, and 20B, the reductions were more modest (14%, 19%, and 24%, respectively). Standardization had little effect for the remaining serotypes. In many cases, the impact of normalization was blunted by the results from five sera that were collected after an extended post-vaccination interval. We have previously reported consensus values for 007sp for 13 serotypes, as well as the creation of a calibration serum panel ("Ewha Panel A"). Here, we report consensus values for 11 additional serotypes for 007sp and the creation of a second serum panel ("Ewha Panel B"). These consensus values will facilitate the development of next-generation PCVs.